Glycoproteins
- Name
- Glycoproteins
- Accession Number
- DBCAT000083
- Description
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
- Drugs
Drug Drug Description Pegfilgrastim A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. Alpha-1-proteinase inhibitor A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency. Filgrastim A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Thyroglobulin For the treatment of hypothyroidism (deficiency in the production of thyroid hormone). Human C1-esterase inhibitor A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema. Protein C A medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis. Protein S human A medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy. Avidin Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach). TG4010 Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer. Tecemotide Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung. PRM-151 PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis). Lactoferrin Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis). Darbepoetin alfa A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Erythropoietin A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Sargramostim A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. Drotrecogin alfa A form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII. Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Adecatumumab Investigated for use/treatment in breast cancer and prostate cancer. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Regramostim Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant. Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. Thrombomodulin Alfa Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. Pegdinetanib Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration. Thrombopoietin Investigated for use/treatment in thrombocytopenia. Methoxy polyethylene glycol-epoetin beta A synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease. Conestat alfa A recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. Gastric intrinsic factor Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic... Epoetin delta Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo. Muplestim Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in... Molgramostim Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis. Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Lenograstim A granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors. Lipegfilgrastim A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. Sulglicotide Not Annotated Eflapegrastim Eflapegrastim is under investigation in clinical trial NCT02953340 (Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide... Recombinant CD40-ligand Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma). Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Fibronectin Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix). Tengonermin Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.... - Drugs & Drug Targets